Cuorips Inc. (4894.T)
JPY 4585.0
(-4.18%)
JPY 4585.0
(-4.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 200.96 Million JPY | 50.2% |
| 2022 | 133.79 Million JPY | -10.42% |
| 2021 | 149.36 Million JPY | 5.22% |
| 2020 | 141.95 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 186.44 Million JPY | -7.22% |
| 2023 Q2 | 223.9 Million JPY | 53.04% |
| 2023 FY | 200.96 Million JPY | 50.2% |
| 2023 Q4 | 200.96 Million JPY | 4.22% |
| 2023 Q3 | 192.82 Million JPY | -13.88% |
| 2023 Q1 | 146.31 Million JPY | 9.35% |
| 2022 FY | 133.79 Million JPY | -10.42% |
| 2022 Q3 | - JPY | 0.0% |
| 2022 Q4 | 133.79 Million JPY | 0.0% |
| 2021 FY | 149.36 Million JPY | 5.22% |
| 2020 FY | 141.95 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 93.811% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -216.918% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.237% |
| Linical Co., Ltd. | 10.3 Billion JPY | 98.05% |
| Trans Genic Inc. | 3.81 Billion JPY | 94.729% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 65.951% |
| Soiken Holdings Inc. | 697.02 Million JPY | 71.169% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 93.347% |
| AnGes, Inc. | 2.78 Billion JPY | 92.795% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 60.873% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.778% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 43.114% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 87.82% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 57.456% |
| CanBas Co., Ltd. | 91.98 Million JPY | -118.464% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 81.624% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 75.185% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 66.153% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 95.276% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.31% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 64.526% |
| Ribomic Inc. | 155.8 Million JPY | -28.979% |
| SanBio Company Limited | 2.25 Billion JPY | 91.088% |
| Healios K.K. | 11.28 Billion JPY | 98.219% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 20.022% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 45.539% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 16.785% |
| StemRIM | 187 Million JPY | -7.466% |
| CellSource Co., Ltd. | 677.73 Million JPY | 70.348% |
| FunPep Company Limited | 189.32 Million JPY | -6.147% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 66.336% |
| Stella Pharma Corporation | 1.44 Billion JPY | 86.079% |
| TMS Co., Ltd. | 97.68 Million JPY | -105.715% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -119.644% |
| K Pharma,Inc. | 209.13 Million JPY | 3.908% |
| Takara Bio Inc. | 11.42 Billion JPY | 98.24% |
| ReproCELL Incorporated | 741.03 Million JPY | 72.881% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 78.102% |
| StemCell Institute Inc. | 3.85 Billion JPY | 94.781% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 77.878% |
| CellSeed Inc. | 301.04 Million JPY | 33.246% |